Tempia-Caliera Adrien A, Ksontini Riadh, Moradpour Darius, Denys Alban, Halkic Nermin
Service de chirurgie viscérale, CHUV, 1011 Lausanne.
Rev Med Suisse. 2005 Jun 15;1(24):1621-4, 1627-9.
The treatment of the hepatocellular carcinoma (HCC) is multidisciplinary. Hepatic transplantation offers the best chances of survival for patients with hepatic cirrhosis and HCC. However the indications for transplantation are limited. For patients that do not qualify for liver transplantation, surgical excision and percutaneous ablative treatment can also be curative. Five years survival then reaches 50%. The choice of treatment is based upon the patient's clinical state, the hepatic function and the cancer clinical stage. Follow-up is crucial as recurrences can be treated by following similar algorithms. The efficacy of oncological adjuvant and neoadjuvant treatment is not yet proved.
肝细胞癌（HCC）的治疗是多学科的。肝移植为肝硬化合并HCC患者提供了最佳的生存机会。然而，移植的适应证有限。对于不符合肝移植条件的患者，手术切除和经皮消融治疗也可能治愈。此时五年生存率可达50%。治疗方案的选择基于患者的临床状态、肝功能和癌症临床分期。随访至关重要，因为复发时可按照类似的算法进行治疗。肿瘤辅助治疗和新辅助治疗的疗效尚未得到证实。
